Do analysts prefer BKHA or ADCT?

ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 241.30%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation and earnings, BKHA or ADCT?

Black Hawk Acquisition has higher earnings, but lower revenue than ADC Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A ADC Therapeutics $81.36M 2.30 -$142.62M -$0.66 N/A

Is BKHA or ADCT more profitable?

Black Hawk Acquisition has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A ADC Therapeutics -121.77% N/A -32.74%

Does the media refer more to BKHA or ADCT?

In the previous week, Black Hawk Acquisition had 7 more articles in the media than ADC Therapeutics. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 8 mentions for ADC Therapeutics. Black Hawk Acquisition's average media sentiment score of 0.28 beat ADC Therapeutics' score of 0.06 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CGEN or BKHA?

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, CGEN or BKHA?

Compugen has higher revenue and earnings than Black Hawk Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 2.60 $35.34M $0.38 5.26 Black Hawk Acquisition N/A N/A N/A N/A N/A

Does the media favor CGEN or BKHA?

In the previous week, Black Hawk Acquisition had 11 more articles in the media than Compugen. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 4 mentions for Compugen. Compugen's average media sentiment score of 0.40 beat Black Hawk Acquisition's score of 0.28 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Hawk Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BKHA or WHWK?

Whitehawk Therapeutics has a consensus price target of $8.33, indicating a potential upside of 180.58%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Whitehawk Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has higher valuation and earnings, BKHA or WHWK?

Black Hawk Acquisition has higher earnings, but lower revenue than Whitehawk Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Whitehawk Therapeutics $7.14M 23.71 -$20.60M -$1.12 N/A

Is BKHA or WHWK more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Whitehawk Therapeutics N/A -53.89% -49.97%

Does the media refer more to BKHA or WHWK?

In the previous week, Black Hawk Acquisition had 12 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.71 beat Black Hawk Acquisition's score of 0.28 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ELDN or BKHA?

Eledon Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 344.44%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, ELDN or BKHA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A Black Hawk Acquisition N/A N/A N/A N/A N/A

Is ELDN or BKHA more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% Black Hawk Acquisition N/A N/A N/A

Do analysts recommend BKHA or ADAG?

Adagene has a consensus price target of $8.67, suggesting a potential upside of 278.46%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger valuation and earnings, BKHA or ADAG?

Black Hawk Acquisition has higher earnings, but lower revenue than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Adagene $7.67M 19.72 -$17.61M N/A N/A

Is BKHA or ADAG more profitable?

Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A Adagene N/A N/A N/A

Does the media refer more to BKHA or ADAG?

In the previous week, Black Hawk Acquisition had 10 more articles in the media than Adagene. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 5 mentions for Adagene. Adagene's average media sentiment score of 0.84 beat Black Hawk Acquisition's score of 0.28 indicating that Adagene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Hawk Acquisition (BKHA) Competitors

$7.74 -4.74 (-37.98%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$7.13 -0.61 (-7.88%)

As of 09:06 AM Eastern

Compare

BKHA vs. ADCT, CGEN, WHWK, ELDN, and ADAG

Should you buy Black Hawk Acquisition stock or one of its competitors? Black Hawk Acquisition's main competitors and comparable companies include ADC Therapeutics (ADCT), Compugen (CGEN), Whitehawk Therapeutics (WHWK), Eledon Pharmaceuticals (ELDN), and Adagene (ADAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Hawk Acquisition compare to ADC Therapeutics?

Black Hawk Acquisition (NASDAQ:BKHA) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

ADC Therapeutics has a consensus price target of $5.00, indicating a potential upside of 241.30%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Black Hawk Acquisition has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the broader market.

Black Hawk Acquisition has higher earnings, but lower revenue than ADC Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
ADC Therapeutics	$81.36M	2.30	-$142.62M	-$0.66	N/A

Black Hawk Acquisition has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
ADC Therapeutics	-121.77%	N/A	-32.74%

In the previous week, Black Hawk Acquisition had 7 more articles in the media than ADC Therapeutics. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 8 mentions for ADC Therapeutics. Black Hawk Acquisition's average media sentiment score of 0.28 beat ADC Therapeutics' score of 0.06 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADC Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.1% of ADC Therapeutics shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ADC Therapeutics beats Black Hawk Acquisition on 7 of the 11 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Compugen?

Compugen (NASDAQ:CGEN) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Compugen has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Compugen has higher revenue and earnings than Black Hawk Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

12.2% of Compugen shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Compugen has a net margin of 47.56% compared to Black Hawk Acquisition's net margin of 0.00%. Compugen's return on equity of 42.57% beat Black Hawk Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Black Hawk Acquisition	N/A	N/A	N/A

In the previous week, Black Hawk Acquisition had 11 more articles in the media than Compugen. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 4 mentions for Compugen. Compugen's average media sentiment score of 0.40 beat Black Hawk Acquisition's score of 0.28 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Hawk Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compugen beats Black Hawk Acquisition on 12 of the 13 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Whitehawk Therapeutics?

Black Hawk Acquisition (NASDAQ:BKHA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Black Hawk Acquisition had 12 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 3 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.71 beat Black Hawk Acquisition's score of 0.28 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Hawk Acquisition's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Whitehawk Therapeutics	N/A	-53.89%	-49.97%

Whitehawk Therapeutics has a consensus price target of $8.33, indicating a potential upside of 180.58%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Whitehawk Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Black Hawk Acquisition has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Black Hawk Acquisition has higher earnings, but lower revenue than Whitehawk Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Whitehawk Therapeutics	$7.14M	23.71	-$20.60M	-$1.12	N/A

Summary

Whitehawk Therapeutics beats Black Hawk Acquisition on 8 of the 11 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Black Hawk Acquisition (NASDAQ:BKHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Eledon Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 344.44%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Black Hawk Acquisition had 14 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.82 beat Black Hawk Acquisition's score of 0.28 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Very Positive
Black Hawk Acquisition	Neutral

Black Hawk Acquisition's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Black Hawk Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A

Eledon Pharmaceuticals has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Black Hawk Acquisition has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Summary

Eledon Pharmaceuticals beats Black Hawk Acquisition on 7 of the 10 factors compared between the two stocks.

How does Black Hawk Acquisition compare to Adagene?

Black Hawk Acquisition (NASDAQ:BKHA) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Black Hawk Acquisition had 10 more articles in the media than Adagene. MarketBeat recorded 15 mentions for Black Hawk Acquisition and 5 mentions for Adagene. Adagene's average media sentiment score of 0.84 beat Black Hawk Acquisition's score of 0.28 indicating that Adagene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Adagene shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Adagene	N/A	N/A	N/A

Black Hawk Acquisition has higher earnings, but lower revenue than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Adagene	$7.67M	19.72	-$17.61M	N/A	N/A

Adagene has a consensus price target of $8.67, suggesting a potential upside of 278.46%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Black Hawk Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Adagene has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

Adagene beats Black Hawk Acquisition on 9 of the 10 factors compared between the two stocks.

Get Black Hawk Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BKHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BKHA vs. The Competition

Export

Metric	Black Hawk Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$51.84M	$3.85B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	N/A	11.31	223.62	21.16
Price / Sales	N/A	1,095.46	547.34	66.59
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	N/A	15.74	10.22	5.92
Net Income	N/A	-$22.69M	$3.50B	$380.90M
7 Day Performance	-36.51%	-5.85%	-3.50%	-3.90%
1 Month Performance	-35.09%	-12.91%	-7.78%	-6.42%
1 Year Performance	-30.30%	2.96%	0.79%	-6.02%

Black Hawk Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BKHA Black Hawk Acquisition	N/A	$7.74 -38.0%	N/A	-29.8%	$51.84M	N/A	N/A	2	News Coverage Gap Down High Trading Volume
ADCT ADC Therapeutics	1.8111 of 5 stars	$1.72 +7.9%	$5.00 +191.5%	-64.3%	$202.99M	$81.36M	N/A	191
CGEN Compugen	3.273 of 5 stars	$2.13 +0.5%	$5.00 +134.7%	-5.2%	$200.45M	$72.76M	5.61	75	Analyst Forecast
WHWK Whitehawk Therapeutics	2.3055 of 5 stars	$3.52 +1.4%	$8.33 +136.7%	+50.8%	$197.82M	N/A	N/A	23	News Coverage
ELDN Eledon Pharmaceuticals	2.2414 of 5 stars	$2.48 +2.5%	$10.00 +303.2%	-17.0%	$196.65M	N/A	N/A	33

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BKHA) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Hawk Acquisition (BKHA) Competitors

BKHA vs. ADCT, CGEN, WHWK, ELDN, and ADAG

How does Black Hawk Acquisition compare to ADC Therapeutics?

Summary

How does Black Hawk Acquisition compare to Compugen?

Summary

How does Black Hawk Acquisition compare to Whitehawk Therapeutics?

Summary

How does Black Hawk Acquisition compare to Eledon Pharmaceuticals?

Summary

How does Black Hawk Acquisition compare to Adagene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA vs. The Competition

Black Hawk Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Hawk Acquisition (BKHA) Competitors

BKHA vs. ADCT, CGEN, WHWK, ELDN, and ADAG

How does Black Hawk Acquisition compare to ADC Therapeutics?

Do analysts prefer BKHA or ADCT?

Which has more risk & volatility, BKHA or ADCT?

Which has better valuation and earnings, BKHA or ADCT?

Is BKHA or ADCT more profitable?

Does the media refer more to BKHA or ADCT?

Do insiders & institutionals believe in BKHA or ADCT?

Summary

How does Black Hawk Acquisition compare to Compugen?

Which has more risk and volatility, CGEN or BKHA?

Which has stronger earnings & valuation, CGEN or BKHA?

Do insiders and institutionals believe in CGEN or BKHA?

Do analysts prefer CGEN or BKHA?

Is CGEN or BKHA more profitable?

Does the media favor CGEN or BKHA?

Summary

How does Black Hawk Acquisition compare to Whitehawk Therapeutics?

Does the media refer more to BKHA or WHWK?

Is BKHA or WHWK more profitable?

Do analysts recommend BKHA or WHWK?

Do institutionals & insiders believe in BKHA or WHWK?

Which has more volatility & risk, BKHA or WHWK?

Which has higher valuation and earnings, BKHA or WHWK?

Summary

How does Black Hawk Acquisition compare to Eledon Pharmaceuticals?

Do analysts recommend ELDN or BKHA?

Do insiders & institutionals have more ownership in ELDN or BKHA?

Does the media favor ELDN or BKHA?

Is ELDN or BKHA more profitable?

Which has better valuation & earnings, ELDN or BKHA?

Which has more risk and volatility, ELDN or BKHA?

Summary

How does Black Hawk Acquisition compare to Adagene?

Does the media refer more to BKHA or ADAG?

Do institutionals and insiders hold more shares of BKHA or ADAG?

Is BKHA or ADAG more profitable?

Which has stronger valuation and earnings, BKHA or ADAG?

Do analysts recommend BKHA or ADAG?

Which has more volatility and risk, BKHA or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BKHA vs. The Competition

Black Hawk Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools